IDHIFA Dosage
Generic name: ENASIDENIB MESYLATE 50mg
Dosage form: tablet, film coated
Drug class: Miscellaneous antineoplastics
Medically reviewed by Drugs.com. Last updated on Jan 16, 2025.
Patient Selection
Select patients for the treatment of AML with IDHIFA based on the presence of IDH2 mutations in the blood or bone marrow.
Interrupt dosing or reduce dose for toxicities. See Table 1 for dosage modification guidelines.
*Grade 1 is mild, Grade 2 is moderate, Grade 3 is serious, Grade 4 is life-threatening. | |
Adverse Reaction |
Recommended Action |
|
|
|
|
|
|
|
|
Frequently asked questions
- How long does it take for Idhifa to start working?
- How does Idhifa work in acute myeloid leukemia (AML)?
- Can Idhifa cause differentiation syndrome?
- What is Idhifa used to treat?
More about Idhifa (enasidenib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Daunorubicin
Daunorubicin systemic is used for acute lymphocytic leukemia, acute myeloid leukemia, acute ...
Revumenib
Revumenib systemic is used for acute lymphoblastic leukemia, acute myeloid leukemia, leukemia
Ivosidenib
Ivosidenib systemic is used for acute myeloid leukemia, biliary tract tumor, myelodysplastic syndrome
Azacitidine
Azacitidine systemic is used for acute myeloid leukemia, myelodysplastic syndrome
Cytarabine
Cytarabine systemic is used for acute myeloid leukemia, acute nonlymphocytic leukemia, chronic ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.